Leerink Partnrs Comments on Beta Bionics FY2024 Earnings

Beta Bionics, Inc. (NASDAQ:BBNX) – Research analysts at Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for Beta Bionics in a report issued on Monday, February 24th. Leerink Partnrs analyst M. Kratky forecasts that the company will post earnings of ($1.66) per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Beta Bionics’ Q4 2024 earnings at ($0.42) EPS, Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.82) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($2.28) EPS, FY2028 earnings at ($1.42) EPS and FY2029 earnings at ($0.95) EPS.

A number of other research analysts also recently weighed in on BBNX. Bank of America began coverage on shares of Beta Bionics in a research report on Monday. They issued a “buy” rating for the company. Piper Sandler initiated coverage on shares of Beta Bionics in a research report on Monday. They issued an “overweight” rating and a $26.00 target price for the company. Stifel Nicolaus started coverage on Beta Bionics in a report on Monday. They issued a “buy” rating and a $25.00 price target for the company. Robert W. Baird started coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price objective for the company. Finally, Baird R W raised Beta Bionics to a “hold” rating in a research report on Thursday, February 20th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Beta Bionics has a consensus rating of “Moderate Buy” and an average target price of $24.83.

Beta Bionics Stock Up 4.3 %

Shares of NASDAQ:BBNX opened at $19.99 on Wednesday. Beta Bionics has a 12-month low of $18.67 and a 12-month high of $24.50.

Insider Buying and Selling

In other Beta Bionics news, insider Mike Mensinger acquired 33,350 shares of the stock in a transaction dated Friday, January 31st. The stock was acquired at an average cost of $17.00 per share, with a total value of $566,950.00. Following the transaction, the insider now owns 59,019 shares in the company, valued at $1,003,323. The trade was a 129.92 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the transaction, the insider now owns 3,901,599 shares in the company, valued at approximately $66,327,183. This represents a 34.46 % increase in their position. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.